<?xml version="1.0" encoding="UTF-8"?>
<p>Our findings show the importance of 
 <italic>Usp18</italic> in immune activation after systemic challenge with VSV or VSV-EBOV. We next analyzed viral replication, localization and immune activation after subcutaneous injection of VSV-EBOV. In line with previous findings, 
 <italic>CD169</italic>-Cre
 <sup>+/
  <italic>ki</italic>
 </sup> x 
 <italic>Usp18</italic>
 <sup>fl/fl</sup> mice showed reduced VSV-EBOV titers (
 <xref ref-type="fig" rid="vaccines-08-00142-f004">Figure 4</xref>A), as well as reduced VSV NP expression (
 <xref ref-type="fig" rid="vaccines-08-00142-f004">Figure 4</xref>B) compared to WT mice. As expected, upon the immunohistological analysis of lymph node sections, staining for Ebola virus GP (red) colocalized with CD169
 <sup>+</sup> MÎ¦s (blue) (
 <xref ref-type="fig" rid="vaccines-08-00142-f004">Figure 4</xref>C). In contrast, 
 <italic>CD169</italic>-Cre
 <sup>+/
  <italic>ki</italic>
 </sup> x 
 <italic>Usp18</italic>
 <sup>fl/fl</sup> did not show staining for Ebola virus GP. In line with these data, 
 <italic>CD169</italic>-Cre
 <sup>+/
  <italic>ki</italic>
 </sup> x 
 <italic>Usp18</italic>
 <sup>fl/fl</sup> showed a highly reduced induction of 
 <italic>Ifna4</italic> and 
 <italic>Ifnb1</italic> (
 <xref ref-type="fig" rid="vaccines-08-00142-f004">Figure 4</xref>D).
</p>
